logo

For the Inventor, By the Inventor

Tampa, FL, United States of America

Sheng Wei

This inventor holds 9 USPTO granted patents and 13 published patent applications and 1 EPO patent. Top assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida. Active years: 2018-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sheng Wei. Retrieved from https://idiyas.com/inventor/sheng-wei-wjuk5ztw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.2

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:

goldMedal9 out of 312 
 
H. Lee Moffitt Cancer Center and Research Institute, Inc.
 patents
silverMedal1 out of 1,990 
 
University of South Florida
 patents
where one patent can have more than one assignee

Years Active: 2018-2024

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents
1. 11976104 - TLR9 ligand trap (2024-05-07),
2. 11584787 - Soluble CD33 for treating myelodysplastic syndromes (MDS) (2023-02-21),
3. 11287428 - PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia (2022-03-29),
4. 11286306 - TLR9-binding chimeric antigen receptors (2022-03-29),
5. 11123435 - TLR9 targeted therapeutics (2021-09-21),
6. 10688077 - Inflammasome activation in myelodysplastic syndromes (2020-06-23),
7. 10682417 - Targeted sensitization of non-del(5q) malignant cells (2020-06-16),
8. 10344072 - Soluble CD33 for treating myelodysplastic syndromes (MDS) (2019-07-09),
9. 9956294 - Targeted sensitization of non-del(5q) malignant cells (2018-05-01),

Title: Innovations and Contributions of Inventor Sheng Wei

Introduction

Sheng Wei is a prominent inventor based in Tampa, Florida, known for his significant contributions to the field of medical research. With a total of nine patents to his name, he has made remarkable strides in understanding and treating myelodysplastic syndromes (MDS) through innovative approaches.

Latest Patents

Among his latest patents is the development of a TLR9 ligand trap aimed at addressing MDS. This invention focuses on the translocation of endosomal Toll-Like receptor (TLR)-9 to the plasma membrane of hematopoietic stem and progenitor cells (HSPC). By sensitizing these cells to respective ligands in their microenvironment, the invention targets important danger-associated molecular patterns (DAMPs) that trigger innate immune activation and contribute to MDS pathogenesis. Additionally, he has developed a soluble CD33 composition for treating MDS, which involves a CD33/S100A9 inhibitor to combat diseases exacerbated by S100A9 activity.

Career Highlights

Sheng Wei has worked with esteemed institutions such as the H. Lee Moffitt Cancer Center and Research Institute and the University of South Florida. His work has been pivotal in advancing the understanding of MDS and developing therapeutic strategies to combat this condition.

Collaborations

Throughout his career, Sheng Wei has collaborated with notable professionals in the field, including Alan F. List and Daniel Abate-Daga. These collaborations have further enriched his research and contributed to the development of innovative solutions in medical science.

Conclusion

Sheng Wei's contributions to the field of medical research, particularly in the area of myelodysplastic syndromes, highlight his role as a leading inventor. His innovative patents and collaborations reflect his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…